Rockville, Md.-based REGENXBIO snagged $100 million from Novartis under its license agreement with gene-therapy company AveXis, which the Swiss company acquired for $8.7 billion earlier in 2018.
Johnson & Johnson received a binding offer to sell its Advanced Sterilization Products (ASP) business to Fortive Corporation. The deal is valued at $2.8 billion.
The tenth annual Dealmakers’ Intentions Study from Syneos Health Consulting, an industry-leading consulting firm specializing in the biopharmaceutical industry, concludes that the dealmaking environment will continue to accelerate with buyers becoming more selective in ensuring they have the most appropriate assets and corresponding deals in place.
Chinese e-commerce giant Alibaba Group Holding Ltd. will inject some of its online pharmacy business into a listed unit in a deal valued at HK$10.6 billion ($1.35 billion), the firm said in a statement.
Ahead of Takeda Pharmaceutical’s acquisition of Dublin-based Shire, the Japan-based company is divesting its majority stake in a Chinese joint venture for about $280 million.
Hearing aid makers Widex and Sivantos are merging to create an industry No. 3 that can invest more in digital devices and step up the challenge to market leaders Sonova and William Demant.
Dublin-based Shire agreed to be acquired by Japan-based Takeda Pharmaceutical, with both boards approving the deal.
U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement.
Paris-based Sanofi agreed to sell the company’s generics division Zentiva to the private equity firm Advent International for 1.9 billion euros ($2.4 billion). The deal is expected to wrap by year-end 2018.